Hansoh Pharmaceutical Group Company Limited (HNSPF)

Market Cap	24.00B +43.3%
Revenue (ttm)	2.15B +22.6%
Net Income	794.27M +27.1%
EPS	0.13 +26.4%
Shares Out	n/a
PE Ratio	30.21
Forward PE	27.44
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	4.489
Previous Close	4.489
Day's Range	4.489 - 4.489
52-Week Range	2.700 - 5.200
Beta	0.55
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 18, 2026

About HNSPF

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 9,347
• Stock Exchange: OTCMKTS
• Ticker Symbol: HNSPF

Financial Performance

In 2025, HNSPF's revenue was 15.03 billion, an increase of 22.57% compared to the previous year's 12.26 billion. Earnings were 5.56 billion, an increase of 27.07%.

Financial numbers in CNY